HSP90AB1 and classic Hodgkin lymphoma: BCR downstream pathways are subsequently impacted by HSP90 inhibition, as demonstrated in MCL, classical Hodgkin lymphoma (cHL), and ABC-DLBCL, where IkB degradation and reduction of NFkB signaling are observed [62,63,69].